Question - Pulmonary toxicity has been identified as the major dose-limiting side effect of treatment with the antineoplastic drug bleomycin. What factors are associated with increased risk for bleomycin pulmonary toxicity?
Answer - The cited reference notes “Bleomycin pulmonary toxicity is associated with the cumulative bleomycin dose, renal function, age and smoking status and can be avoided by a careful patient evaluation before chemotherapy.” (Haugnes HS et al. Pulmonary and cardiovascular toxicity in long term testicular cancer survivors. 2015 Urol Onc 33:399-406)